OncoMatch/Clinical Trials/NCT02332668
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Is NCT02332668 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Pembrolizumab for melanoma.
Treatment: Pembrolizumab — Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away. With Amendment 8, enrolment of participants with solid tumours and participants 6 months to under 12 years old with melanoma were closed. Enrolment of participants 12-18 years old with melanoma continues. Enrolment of participants who have tumours with specific traits (microsatellite-instability-high (MSI-H), and tumour-mutational burden-high ≥10 mutation/Mb (TMB-H)) also continues.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Non-Hodgkin Lymphoma
Tumor Agnostic
Hodgkin Lymphoma
Biomarker criteria
Required: PD-L1 (CD274) positive (positive)
Disease stage
Required: Stage III, IV
locally-advanced, or metastatic solid malignancy or lymphoma that is incurable and has failed prior standard therapy
Prior therapy
Must have received: standard therapy
has failed prior standard therapy, or for which no standard therapy exists, or for which no standard therapy is considered appropriate
Cannot have received: anti-PD-1 therapy
Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand 1 (anti-PD-L1), anti-PD-L2 agent, or any agent directed to another stimulatory or inhibitory T-cell receptor (eg, cytotoxic lymphocyte associated protein-4 [CTLA-4], OX-40, CD137)
Cannot have received: systemic anti-cancer therapy
Exception: within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent
Prior systemic anti-cancer therapy including investigational agent within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent
Cannot have received: radiotherapy
Exception: within 2 weeks of start of study treatment
Prior radiotherapy within 2 weeks of start of study treatment
Cannot have received: investigational agent
Exception: within 4 weeks of the date of allocation/randomization
participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the date of allocation/randomization
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Demonstrate adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Call for Information (Investigational Site 0019) · Aurora, Colorado
- Call for Information (Investigational Site 0026) · Boston, Massachusetts
- Call for Information (Investigational Site 0031) · New York, New York
- Call for Information (Investigational Site 0070) · Fargo, North Dakota
- Call for Information (Investigational Site 0032) · Cincinnati, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify